Oxidative metabolites of 5-S-cysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the α-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes: Possible implications for neurodegenerative brain disorders

Chemical Research in Toxicology

Volumn 13, Issue 8, 2000, Pages 749-760

  Xin, W ^a   Shen, X M ^a   Li, H ^a   Dryhurst, G ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 S CYSTEINYLNOREPINEPHRINE; 7 (1 HYDROXY 2 AMINOETHYL) 3,4 DIHYDRO 5 HYDROXY 2H 1,4 BENZOTHIAZINE 3 CARBOXYLIC ACID; GLUTATHIONE; NORADRENALIN DERIVATIVE; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE COMPLEX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; BRAIN MITOCHONDRION; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE TIME EFFECT RELATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; RAT;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTRON TRANSPORT COMPLEX III; ENZYME INHIBITORS; KETOGLUTARATE DEHYDROGENASE COMPLEX; MALE; MITOCHONDRIA; MULTIENZYME COMPLEXES; NOREPINEPHRINE; OXIDATION-REDUCTION; PARKINSON DISEASE; PYRUVATE DEHYDROGENASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; THIAZINES;

ANIMALIA;

EID: 0033845074     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx990170t     Document Type: Article

References (72)

1. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders
2. Animal models of Parkinson's disease: An empirical comparison of the phenomenology of the disease in man
3. Inhibitors of mitochondrial respiration, iron(II) and hydroxyl radical, evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: Potential implications to Parkinson's disease
4. +
5. Energy driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP
6. Mitochondrial dysfunction in neurodegeneration
7. Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion
8. Parkinson's disease and brain levels of organochlorine pesticides
9. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures
10. Parkinson's after exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate)
11. The effect of dithiocarbamates on neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and on mitochondrial respiration chain
12. The ageing liver: Drug clearance and an oxygen diffusion barrier hypothesis
13. Xenobiotic metabolism in Parkinson's disease
14. Parkinson's disease, pesticides, and glutathione transferase polymorphisms
15. Genetic epidemiology of Parkinson's disease
16. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease
17. Origin and functional consequences of the complex I defect in Parkinson's disease
18. Association between the gene encoding the E2 subunit of the α-ketoglutarate dehydrogenase complex and Parkinson's disease
19. +
20. Screening of thiol compounds: Depolarization-induced release of glutathione and cysteine from rat brain slices
21. Relationships betwen the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes
22. Effect of pyruvate on rat heart thiol status during ischemia and hypoxia followed by reperfusion
23. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition
24. NMDA-dependent superoxide production and neurotoxicity
25. Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: Effect of pH and iron saturation
26. The inactivation of Fe-S cluster containing hydrolyases by superoxide
27. Activated microglia cause superoxide-mediated release of iron from ferritin
28. Role of astrocytes in maintaining cerebral glutathione homeostasis and protecting the brain against xenobiotics and oxidative stress
29. ATP-regulated neuronal catecholamine uptake: A new mechanism
30. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease. Possible mechanisms of formation involving reactive oxygen species
31. Maintenance of neuronal glutathione by glial cells
32. γ-Glutamyl transpeptidase from kidney
33. Transport of cystine and cysteine in mammalian cells
34. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione
35. +)
36. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the depigmentation of substantia nigra
37. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease
38. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-car boxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease
39. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-car boxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: Potential relevance to the pathogenesis of Parkinson's disease
40. Oxidative metabolites of 5-S-cysteinyldopamine inhibit α-ketoglutarate dehydrogenase complex: Potential relevance to the pathogenesis of Parkinson's disease
41. 1 reductase (complex I) deficiency in Parkinson's disease
42. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease
43. Pathology of Parkinson's syndrome
44. Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome
45. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
46. The possible role of noradrenergic deficits in selected signs of Parkinson's disease
47. Oxidation chemistry of(-)-norepinephrine in the presence of L-cysteine
48. Protein measurement with the Folin phenol reagent
49. Reactive oxygen species-mediated inactivation of pyruvate dehydrogenase
50. Brain α-ketoglutarate dehydrogenase complex: Kinetic properties, regional distribution, and effects of inhibitors
51. Oxidation of dopamine in the presence of cysteine: Characterization of new toxic products
52. Mitochondrial NADH:ubiquinone reductase: Complementary DNA sequence of the import precursors of the bovine 75-kDa subunit
53. The amino acid sequences of two 13 kDa polypeptides and partial amino acid sequence of 30 kDa polypeptide of complex I from bovine heart mitochondria: Possible location of iron-sulfur clusters
54. Interaction between catalytic and regulatory sites of the pyruvate dehydrogenase from Escherichia coli studied by the ESR technique
55. Identification of the essential cysteine residue in the active site of bovine pyruvate dehydrogenase
56. Regulation of α-ketoglutarate dehydrogenase cooperative properties in substrate binding by thiol-disulfide exchange
57. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia
58. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
59. Biochemical changes associated with selective neuronal death following short-term cerebral ischaemia
60. Intraischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia
61. Substantia nigra lesion protects against ischemic damage in the striatum
62. Direct evidence for acute and massive norepinephrine release in the hippocampus during transient ischemia
63. Cerebral norepinephrine depletion enhances recovery after brain ischemia
64. Influence of complete and pronounced incomplete cerebral ischemia and subsequent recirculation on cortical concentrations of oxidized and reduced glutathione in the rat
65. Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain
66. Brain ischemia markedly elevates levels of the neurotoxic amino acid, cysteine
67. Lowered brain glutathione by diethylmaleate decreased the glutamate release by cerebral ischemia in anesthetized rats
68. The changing landscape of ischaemic brain injury mechanisms
69. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia
70. Altered mitochondrial respiration in selectively vulnerable brain subregions following transient forebrain ischemia in the rat
71. Reduced activity of the pyruvate dehydrogenase complex but not cytochrome c oxidase is associated with neuronal loss in the striatum following short-term forebrain ischemia